In vitro: Loss of function of CSK or PTEN confers resistance to both lapatinib and trastuzumab in Human epidermal growth factor receptor 2 (HER2)-amplified gastric cancer (GC) cells.
In vivo: Trastuzumab exerts antitumor effects in ERBB2-positive AFPGC PDX models, in which statistically significant differences are present in the tumor volume between the group treated with AZD5438 combined with trastuzumab and those treated with AZD5438 or trastuzumab alone in ERBB2 and CCNE1 co-amplified PDX models.
My Review for Humanized Anti-Human HER2 (Trastuzumab) Monoclonal antibody, clone Trastuzumab
Creative Diagnostics products are for RESEARCH USE ONLY, please make sure your review is research based.
Required fields are marked with *
Terms and conditions:
We will select high-quality review customers and offer a $30 coupon for your next purchase.
All product reviews must be submitted in the English language.
Creative Diagnostics will not share any personal information of applicants, and all information will be treated with strict confidentiality and will not be sold or disclosed to a third party.
COA
Publication 
Loading ......
